US plans to test Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports

The Trump administration is reportedly considering a five-year pilot program to expand Medicare and Medicaid coverage for GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, marking a significant policy reversal. This potential move, despite the drugs' high annual cost of $5,000-$7,000, signals a substantial market expansion for pharmaceutical companies, evidenced by Eli Lilly's 2% stock rise and Novo Nordisk's 1.2% gain. Conversely, the prospect of broader public coverage negatively impacted telehealth platforms like Hims & Hers Health, which fell 6% due to anticipated reduced demand for compounded alternatives, while raising long-term affordability questions for government healthcare programs.

Analysis

The potential for a five-year pilot program to cover GLP-1 weight-loss drugs under Medicare and Medicaid represents a significant potential policy reversal and a major catalyst for the sector. This development, which would include Novo Nordisk's Wegovy and Eli Lilly's Zepbound, has been met with a positive market reaction, evidenced by Eli Lilly's shares rising over 2% and Novo Nordisk's gaining 1.2%. The proposed program would substantially expand the addressable market by tapping into the 65 million Medicare and 70 million Medicaid enrollees, a move described by a Needham analyst as a "big shift in view" from previous cost-containment stances. However, the high annual cost of the drugs, cited at $5,000 to $7,000, raises long-term affordability questions for federal and state governments. The negative impact on alternative providers was also clear, with telehealth platform Hims & Hers Health declining 6% on expectations that broader public coverage for branded drugs will reduce demand for its compounded offerings. The proposed timelines, with a Medicaid pilot in April 2026 and a Medicare pilot in January 2027, frame this as a medium-term, rather than immediate, fundamental driver.

Key Decisions for Investors

• Investors with long positions in Eli Lilly and Novo Nordisk should view this as a significant medium-term catalyst that could dramatically expand their total addressable market, though revenue impact is not expected until 2026-2027 at the earliest.
• The high annual cost of these drugs presents a key risk; investors should monitor for any political or budgetary pushback that could delay, scale down, or cancel the proposed pilot programs.
• The 6% decline in Hims & Hers Health stock highlights a direct competitive threat to companies offering compounded GLP-1 alternatives, warranting a re-evaluation of positions in such firms.
• Consider the forward-looking catalyst for Eli Lilly, as the potential inclusion of its experimental oral weight-loss drug in the pilot could provide an additional long-term competitive advantage over peers.